Germany’s regulatory approach to medical cannabis is good practice and should be replicated across Europe, according to newly-born European Medicinal Cannabis Association (EUMCA).
The recently established lobby group is taking its first steps in the Brussels bubble, advocating for an EU-wide regulatory framework on medical marijuana.
While the market for medical cannabis is already well developed in some EU member states, only EU-wide standards can ensure patients have the same across Europe.
Different legislation across EU countries on prescribing cannabis-based medicines can hinder patients’ access to their treatment when they travel abroad, EUMCA said.
“Our main priority is informing national and EU institutions about the opportunity that this treatment is offering,” said Sita Schubert, secretary general of EUMCA.
Lack of clinical trials is a major reason why doctors are cautious about the drug. But according to Schubert, health actors and lawmakers are also often simply not familiar with medical marijuana.
“The use of cannabis for medical…